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Abstract
Introduction:  Survival  of  transplant  patients  and  grafts  depends  largely  on  the  use  of  immuno-
suppressive  drugs.  However,  a  balance  remains  to  be  established  among  immunosuppression,
transplant  rejection  and  cytomegalovirus  (CMV)  infection,  which  results  in  a  high  rate  of
morbidity and  mortality.  The  aim  of  this  study  was  to  deﬁne  a  better  strategy  for  monitor-
ing transplanted  patients  based  on  the  analysis  of  the  blood  concentration  of  sirolimus  and
tacrolimus  and  the  burden  of  CMV.
Methods:  Fifty  ﬁve  post-transplant  (kidney  and  liver)  pediatric  patients,  nine  treated  with
sirolimus and  46  treated  with  tacrolimus,  were  included.  A  total  of  541  measurements  were
obtained. In  each  measurement  the  concentration  of  immunosuppressant  in  whole  blood  and
CMV viral  load  in  plasma  and  whole  blood  was  quantiﬁed  by  real-time  PCR.  Pearson  correlation
coefﬁcient  (r)  was  estimated.
Results:  Values  of  r  ≤0.0747  were  found  for  the  relationship  between  dose  and  concentration
of immunosuppressant;  r  =  0.9406  for  the  relationship  between  viral  load  in  whole  blood  and
plasma, and  r  ≤0.4616  for  the  relationship  between  concentration  of  immunosuppressant  and
viral load.∗ Corresponding author.
E-mail address: brisalm@yahoo.com.mx (B. López-Martínez).
ttp://dx.doi.org/10.1016/j.bmhimx.2015.12.006
665-1146/© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusions:  These  data  support  that  the  doses  of  immunosuppressive  drugs  do  not  correlate
with the  levels  of  the  same  in  whole  blood.  Therefore,  systemic  levels  of  immunosuppressant
should be  constantly  monitored  together  with  CMV  load.  Meanwhile,  a  high  correlation  between
viral load  measured  in  whole  blood  and  plasma  was  found.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Correlación  entre  la  carga  viral  de  citomegalovirus  y  los  niveles  de  tacrolimus  y
sirolimus  en  pacientes  pediátricos  trasplantados
Resumen
Introducción:  La  supervivencia  de  pacientes  trasplantados  y  de  los  injertos  depende  en  gran
medida del  uso  de  fármacos  inmunosupresores.  Sin  embargo,  aún  no  se  ha  logrado  establecer  un
balance entre  la  inmunosupresión,  el  rechazo  al  trasplante  y  la  infección  por  citomegalovirus
(CMV), lo  cual  deriva  en  una  alta  tasa  de  morbilidad  y  mortalidad.  El  objetivo  de  este  trabajo
fue deﬁnir  una  mejor  estrategia  de  seguimiento  de  los  pacientes  trasplantados  a  partir  del
análisis de  la  concentración  en  sangre  de  sirolimus  y  tacrolimus  y  la  carga  de  CMV.
Métodos:  Se  incluyeron  55  pacientes  pediátricos  post-trasplante  (rin˜ón  e  hígado),  nueve  en
tratamiento  con  sirolimus  y  46  en  tratamiento  con  tacrolimus.  Se  obtuvieron  541  mediciones
en total.  En  cada  medición  se  cuantiﬁcó  la  concentración  de  inmunosupresor  en  sangre  total
y la  carga  viral  de  CMV  en  plasma  y  sangre  total  mediante  PCR  en  tiempo  real.  Se  calculó  el
coeﬁciente  de  correlación  de  Pearson  (r).
Resultados:  Se  encontraron  valores  de  r  ≤  0.0747  para  la  relación  entre  dosis  y  concentración
del inmunosupresor;  de  r  =  0.9406  para  la  relación  de  la  carga  viral  entre  suero  y  sangre  total
y de  r  ≤  0.4616  para  la  relación  entre  concentración  de  inmunosupresor  y  carga  viral.
Conclusiones:  Estos  datos  apoyan  que  la  dosis  de  los  fármacos  inmunosupresores  no  correlaciona
con los  niveles  de  los  mismos  en  sangre  total.  Por  ello,  deben  ser  constantemente  monitoreados
junto con  la  carga  viral.  Por  su  parte,  se  encontró  alta  correlación  entre  la  carga  viral  medida
en sangre  total  y  plasma.
©  2016  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t1. Introduction
Solid  organ  transplant  (SOT)  is  a  viable  option  for  the  treat-
ment  of  childhood  diseases  that  result  in  end  organ  failure.
According  to  the  Organ  Procurement  and  Transplantation
Network  (OPTN)  in  the  U.S.  in  2008,  almost  2000  pediatric
patients  (<18  years)  received  an  organ  transplant,  repre-
senting  7.6%  of  all  transplants  performed.  The  majority  of
those  transplants  were  kidney  followed  by  liver.  Among  the
principal  problems  associated  with  the  transplant  are  graft
rejection  and  infection  due  to  cytomegalovirus  (CMV).1,2
CMV  or  human  herpesvirus  5  was  initially  isolated  from
the  salivary  glands  and  kidneys  of  children.3 It  received
the  name  of  cytomegalovirus  because  it  produces  typical
cytomegalic  inclusions  in  the  affected  cells.4,5 In  1965  it  was
isolated  in  a  kidney  transplant  recipient.6 Infection  caused
by  CMV  is  present  in  90%  of  the  world  population,  usually
7since  childhood. In  patients  who  are  immunocompromised,
such  as  patients  with  SOT,  CMV  is  one  of  the  principal  causes
of  morbidity  and  mortality  because  it  causes  clinical  effects
such  as  viral  syndrome  by  CMV,  fatigue,  organ  failure  and
e
I
u
traft  rejection.8 In  addition,  these  effects  are  associated
ith  an  increase  in  hospitalization  costs.8--12
Despite  advances  in  the  development  of  immunosup-
ressive  agents,  a  balance  between  therapy  to  prevent
ejection  and,  at  the  same  time,  preserve  the  ability  of
he  immune  system  to  control  or  prevent  infectious  pro-
esses  has  not  been  found.  Two  of  the  most  commonly
sed  immunosuppressants  are  tacrolimus  and  sirolimus.  Cur-
ently,  for  management  of  patients  with  SOT,  the  best
trategy  to  prevent  rejection  associated  with  insufﬁcient
oncentrations  of  immunosuppressant  and  CMV  disease  is
o  individualize  therapy.  Preventing  rejection  is  achieved
y  routinely  quantifying  the  immunosuppressant  levels  in
lood  to  keep  them  within  the  therapeutic  range.  In  regard
o  CMV  disease,  prevention  is  carried  out  by  monitoring  the
iral  load  in  whole  blood  and/or  plasma.13--16 The  solid  organ
ransplant  program  of  the  Hospital  Infantil  de  México  Fed-
rico  Gómez  (HIMFG)  is  one  of  the  main  programs  in  Mexico.
n  that  institution  no  studies  have  been  carried  out  that  doc-
ment  the  quantitative  relationship  between  the  dose  and
he  blood  levels  of  the  immunosupresant  or  that  show  the
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elationship  between  the  blood  level  of  the  immunosupp-
essant  and  CMV  viral  load  in  whole  blood  and  in  plasma.
he  goal  of  this  investigation  was  to  describe  the  correla-
ion  between  the  blood  level  of  tacrolimus  and  sirolimus
mmunosuppressant  agents  and  CMV  viral  load  in  pediatric
atients  with  kidney  or  liver  transplant  from  the  HIMFG.
. Methods
.1.  Study  population
he  study  was  conducted  at  the  Clinical  Laboratory
epartment  of  the  HIMFG  between  May  2011  and  June
012.  Pediatric  patients  with  kidney  or  liver  transplant
ho  were  undergoing  immunosuppressant  treatment  with
acrolimus  or  sirolimus  were  included.  The  study  included
ine  post-kidney  transplant  patients  undergoing  ther-
py  with  sirolimus  as  immunosuppressant.  From  these
atients,  13  measurements  were  done.  The  study  also
ncluded  46  patients  undergoing  treatment  with  tacrolimus
s  immunosuppressant  (20  post-liver  transplant  and  26
ost-kidney  transplant).  There  were  528  measurements
one  from  the  group  of  patients  undergoing  therapy  with
acrolimus.
The  study  was  approved  by  the  Scientiﬁc  Research  and
thics  Committees  of  the  HIMFG.  Throughout  the  study  the
dentity  of  the  patients  remained  conﬁdential,  although  the
eries  of  clinical  tests  done  is  part  of  the  routine  follow-up
erformed  after  transplantation  as  a  strategy  to  reduce  the
isk  of  CMV  disease.
.2.  Quantiﬁcation  of  sirolimus  in  whole  blood
or  quantiﬁcation  of  sirolimus,  pre-treatment  using  a
50-l sample  of  whole  blood  and  300  l  precipitating
eagent  from  ARCHITECT  Sirolimus  Whole  Blood  Precipita-
ion  Reagent®  (Abbott  Laboratories)  was  carried  out.  The
ixture  was  incubated  at  42 ◦C  for  10  min.  It  was  then
entrifuged  for  7  min  at  13,000  rpm,  and  the  supernatant
as  separated  in  a  pretreatment  tube  for  immunosup-
ressive  techniques  (1P06-01®,  Abbott  Laboratories).  The
ixture  was  centrifuged  for  30  sec  and  ﬁnally  quantiﬁed
ith  the  ARCHITECT  i1000SR®  (Abbott)  equipment.  The
anufacturer’s  instructions  were  followed  in  all  procedures.
uantiﬁcation  of  the  immunosuppressant  was  reported  in
g/ml.
.3.  Quantiﬁcation  of  tacrolimus  in  whole  blood
or  quantiﬁcation  of  tacrolimus,  pre-treatment  was  carried
ut  by  placing  a  sample  of  200  l whole  blood  and  200  l of
 precipitating  reagent  (ARCHITECT  Tacrolimus  Whole  Blood
recipitation  Reagent®,  Abbott)  in  a  centrifuge  tube  and
hen  using  vortex  agitation  for  7  min.  It  was  then  centrifuged
or  7  min  at  13,000  rpm,  and  the  supernatant  was  separated
n  a  pretreatment  tube  for  immunosuppressive  techniques
1P06-01®,  Abbott  Laboratories).  The  mixture  was  spun  for
0  sec  and  quantiﬁed  in  the  ARCHITECT  i1000SR®  (Abbott)
quipment.
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.4.  Quantiﬁcation  of  CMV
uantiﬁcation  of  CMV  was  done  in  whole  blood  and  plasma
ith  real-time  PCR.  For  this  procedure,  3  ml  of  peripheral
lood  was  obtained  anticoagulated  with  EDTA.  An  aliquot  of
00  l was  separated.  The  remaining  sample  was  centrifuged
t  3000  rpm  for  10  min  and  an  aliquot  of  400  l  of  plasma  was
aken.  For  extraction  of  the  DNA  the  MagNA  Pure  Compact®
Roche  Molecular  Diagnostics)  equipment  was  used  with  a
et  of  reagents  using  MagNA  Pure  Compact  Nucleic  Acid
solation  Kit  I (Roche  Molecular  Diagnostics).  Programs  for
NA  extraction  from  400  l of  peripheral  blood  were  used
ith  an  emulsion  volume  of  200  l,  and  the  program  of
otal  nucleic  acids  from  400  l  of  plasma  with  an  emul-
ion  volume  of  100  l. For  real-time  PCR  a  166-bp  fragment
f  the  CMV  viral  genome  was  ampliﬁed  a  design  from  the
IB  MOLBIOL  Company  and  LightCycler®  equipment  (Roche
olecular  Diagnostics).  As  internal  positive  control  (human
lbumin),  a  set  of  primers  that  ampliﬁes  a  278-bp  fragment
as  used.  Primer  sequences  against  CMV  and  the  albumin
ene  are  not  speciﬁed  by  the  supplier.  The  reaction  mixture
as  brought  to  a  ﬁnal  volume  of  20  l  using  5  l  of  the  DNA
xtracted  from  each  of  the  samples.  The  reaction  mixtures
ere  subjected  to  a  program  of  denaturation  of  the  sample
nd  activation  of  the  enzyme  at  a  temperature  of  95 ◦C  for
0  min,  followed  by  50  ampliﬁcation  cycles  of  5  sec  at  95 ◦C,
0  sec  at  60 ◦C,  15  sec  at  72 ◦C.  Later,  a denaturation  curve
as  performed  to  identify  the  product  of  the  PCR  derived
rom  the  DNA  of  the  CMV,  with  a  program  of  1  cycle  for
0  sec  at  95 ◦C,  20  sec  at  40 ◦C  and  1  sec  at  85 ◦C,  with  an
ncrease  in  temperature  of  0.2 ◦C  sec  and  continuous  ﬂuo-
escence  acquisition  mode.  The  manufacturer’s  instructions
ere  followed  in  all  cases  (Roche  Molecular  Diagnostics).
.5.  Statistical  analysis
o  evaluate  the  correlation  between  study  variables,  Pear-
on  correlation  coefﬁcient  (r)  and  its  respective  statistical
alue  (two-tailed  p value)  were  obtained;  p  <  0.05  was  con-
idered  to  be  statistically  signiﬁcant.  The  statistical  package
raphPad  Prism  v.5.0  for  Windows  (GraphPad  Software,  La
olla  CA,  www.graphpad.com)  was  used.
. Results
he  study  included  nine  patients  with  the  immunosupp-
essant  sirolimus  and  46  patients  with  tacrolimus.  The
mmunosuppressant  dose  varied  from  1  to  3  mg  every  24  h
or  sirolimus  and  from  0.25  to  6  mg  every  12  h  for  tacrolimus.
igure  1  represents  the  correlation  between  the  dose  admin-
stered  and  the  levels  of  immunosuppressant  in  the  blood.
here  were  13  measurements  done  for  sirolimus  and  528
or  tacrolimus.  A  positive  correlation  was  found  between
ariables  in  both  cases,  although  the  Pearson  correlation
oefﬁcient  (r)  was  very  close  to  zero  (r  =  0.0747  for  sirolimus
nd  r  =  0.3037  for  tacrolimus).  In  the  latter  case,  the  corre-
ation  was  statistically  signiﬁcant  (p  =  0.0001).  However,  this
eans  that  only  with  a  30%  certainty  could  one  predict  the
lood  concentration  of  tacrolimus  with  respect  to  the  dose
dministered.  In  relation  to  sirolimus,  there  was  no  corre-
ation  observed  between  the  dose  and  the  concentration
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Figure  1  Comparison  of  dose  vs.  concentration  in  blood  of  the  im
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Figure  2  Comparison  of  the  CMV  viral  load  in  plasma  and
whole  blood.  Pearson  correlation  coefﬁcient  (r)  is  shown  for
the comparison.  Discordant  measurements  are  shown  in  red  in
which  the  viral  load  was  elevated  in  plasma,  but  not  in  whole
blood or  vice-versa.  A  10-base  logarithmic  scale  was  used  for
the graph  in  order  to  better  separate  the  data,  although  the
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the  CMV  viral  load  were  carried  out.  Data  obtained  showPearson correlation  was  calculated  linearly.
in  blood  (p  =  0.79).  Viral  load  of  CMV  in  plasma  vs.  whole
blood  was  compared  with  the  objective  of  identifying  the
variation  shown  between  both  biological  sources  (Fig.  2).
A  positive  high  and  statistically  signiﬁcant  correlation  was
found  (r  =  0.9406,  p  =  0.0001),  which  indicates  that  both
plasma  as  well  as  whole  blood  reliably  reﬂect  the  behavior
of  CMV  in  the  patient  with  immunosuppressive  treatment.
In  nine  measurements,  the  correlation  between  samples
was  very  poor,  with  values  >  5000  copies/ml  in  plasma  vs.
100  copies/ml  in  whole  blood  or  vice-versa,  values  >  5,000
copies/ml  in  whole  blood  and  values  ≤100  copies/ml  in
plasma.  These  cases  are  shown  in  red  points  in  Figure  2.
With  the  aim  of  determining  if  plasma  or  whole  blood  bet-
ter  reﬂects  viral  replication,  the  correlation  between  viral
load  in  plasma  or  whole  blood  and  the  levels  of  immuno-
suppressant  were  analyzed.  According  to  Figure  3  and  as
expected,  there  were  very  similar  degrees  of  correlation
found  between  the  levels  of  immunosuppressant  and  viral
load,  both  in  plasma  as  in  whole  blood.  However,  this  rela-
tionship  had  values  very  close  to  zero.  The  latter  indicates
that  the  evaluation  of  the  immunosuppressant  in  blood  does
not  allow  predicting  if  the  patient  has  an  elevated  CMV  load
and  therefore  is  at  risk  to  develop  an  associated  morbid-
ity.  For  this  reason,  it  is  necessary  to  monitor  the  viral  load
i
N
dmunosuppressant.  (A)  Sirolimus  (13  measurements  from  nine
rson  correlation  coefﬁcient  (r)  is  shown  for  each  comparison.
ogether  with  immunosuppressant  levels  in  the  blood.  All  r
alues  and  the  respective  p  value  are  shown  in  the  graphs.
.  Discussion
s  a strategy  to  prevent  graft  rejection  and  graft  vs.  host
isease,  patients  who  receive  SOT  should  be  pharmaco-
ogically  immunosuppressed.  However,  as  a result  of  this
mmunosuppression,  post-transplant  patients  are  at  risk  of
eveloping  severe  infections.12,17--19 Of  particular  impor-
ance  is  infection  by  the  herpesvirus  family.  More  than
0%  of  the  adult  population  is  infected  by  one  or  various
erpesviruses,  although  the  infection  is  latent  and  asymp-
omatic  in  healthy  individuals.  The  same  does  not  occur
n  individuals  undergoing  immunosuppressive  treatment.  In
hese  patients,  the  equilibrium  of  the  infection  is  altered
nd  patients  can  develop  severe,  life-threatening  diseases.
mong  the  common  problems  due  to  herpesviruses  that
resent  in  patients  with  immunosuppressive  management
re  severe  CMV  infections  and  lymphoproliferative  disease
ue  to  the  Epstein-Barr  virus  (EBV).20 On  the  other  hand,
educing  the  dose  of  the  immunosuppressant  drug  increases
he  risk  of  transplant  rejection  and  graft  vs.  host  disease,
hich  is  also  associated  with  increased  mortality  of  the
ransplant  patient.
Despite  the  increasingly  larger  number  of  immuno-
uppressant  drugs  available  on  the  market,  the  risk  of
evere  infection  by  herpesviruses  continues.  Tacrolimus  and
irolimus  are  two  of  the  main  immunosuppressant  drugs  used
orldwide.21 Both  have  very  similar  structures  and  recog-
ize  FKBP12,  a  chaperone  protein  member  of  the  family
f  the  immunophilins.22 These  compounds  were  originally
solated  from  Streptomyces  hygroscopicus  by  its  potent
mmunosuppressive  activity.  Because  both  drugs  efﬁciently
nd  speciﬁcally  abate  the  cytotoxic  immune  response,  they
re  widely  used  to  prevent  risk  of  transplant  rejection.  How-
ver,  decrease  of  the  cytotoxic  immune  response  results  in
oss  of  infection  control  by  herpesviruses.
This  present  study  analyzed  55  transplant  patients
reated  with  sirolimus  or  tacrolimus  from  which  541  deter-
inations  of  the  circulating  levels  of  the  drugs  and  ofnteresting  trends  and  assist  clinically  in  patient  follow-up.
o  signiﬁcant  association  was  found  between  medication
ose  and  blood  levels.  This  was  reproduced  for  both
8  H.  Reyes-Pérez  et  al.
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Figure  3  Concentration  of  sirolimus  (A-B)  and  tacrolimus  (C-D)  vs.  viral  load  in  plasma  (A,C)  or  whole  blood  (B,D).  Pearson
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gorrelation coefﬁcient  (r)  is  shown  for  each  comparison.  Numb
rder to  better  separate  the  data,  although  Pearson  correlation
mmunosuppressant  agents  analyzed  indicating  that  contin-
ous  drug  monitoring  is  necessary  to  have  a  better  idea
f  its  pharmacological  effect  and  patient  protection.  Both
mmunosuppressant  agents,  sirolimus  and  tacrolimus,  have
 low  therapeutic  index.  Therefore  they  are  considered
s  monitoring  drugs  because  their  circulation  levels  must
e  constantly  evaluated.23 This  is  due  to  the  variability  of
he  pharmacodynamic  and  pharmacokinetic  characteristics
etween  patients.  The  data  presented  agree  with  the  above
nformation.
The  herpesviruses  have  a  two-phase  life  cycle:  latent  and
ytic.  The  latent  phase  is  associated  with  a  cellular  depend-
ncy  in  which  there  is  not  production  of  viral  particles.
n  the  contrary,  the  lytic  phase  could  be  associated  with
iremia.  For  this  reason,  it  is  important  to  ask  oneself:  which
s  the  best  source  of  clinical  sample  for  CMV  analysis?  The
ata  observed  support  that,  for  CMV,  there  is  a  very  close
orrelation  between  viral  load  present  in  whole  blood  and
n  plasma,  at  least  in  patients  who  are  pharmacologically
mmunosuppressed.  Therefore,  with  few  exceptions,  both
lasma  as  well  as  whole  blood  allow  us  to  have  a  good  idea
f  the  viral  expansion  processes  due  to  de  novo  infection
r  reactivation  that  a  transplant  patient  is  experiencing.
f  the  541  measurements  done,  in  only  nine  there  were
alues  found  that  did  not  correlate  in  which  one  of  the
easurements  (in  plasma  or  whole  blood)  showed  values
5000  copies  of  CMV/ml,  whereas  the  other  measurement
howed  negative  or  barely  detectable  CMV  values.  To  date
here  is  no  consensus  about  the  levels  of  CMV  that  require
herapeutic  intervention,  but  the  internal  recommendation
E
P
df  copies  of  CMV  was  graphed  in  a  10-base  logarithmic  scale  in
 calculated  linearly.
n  different  transplant  centers  is  from  ≥5,000  copies  of
MV/ml.24
These  data  also  support  that  the  continuous  monitoring
f  the  viral  load  in  transplant  patients  is  necessary  because
ystemic  levels  of  the  immunosuppressant  do  not  permit
redicting  the  behavior  of  CMV.  This  is  illustrated  not  only
y  the  values  of  the  Pearson  correlation  obtained  but  also
y  the  patients  with  acceptable  immunosuppressive  levels
r  higher  than  recommended  for  age  (>10  ng/ml)  and  viral
oads  >  5,000  copies/ml.
In summary,  the  dose  of  the  immunosuppressant  drug
oes  not  correlate  with  levels  in  peripheral  blood.  For  this
eason,  these  levels  should  be  constantly  monitored  along
ith  the  CMV  load.  Viral  load  measured  in  whole  blood  or
lasma  was  found  to  have  a  high  correlation,  indicating  that
oth  types  of  clinical  samples  are  equally  reliable  in  reﬂect-
ng  the  processes  of  infection/reactivation  by  CMV  due  to
he  immunosuppression  that  the  transplanted  patient  is
xperiencing.  Follow-up  of  the  transplanted  patient  through
uantiﬁcation  of  the  systemic  levels  of  the  immunosuppress-
nt  drugs  and  of  the  viral  loads  of  CMV  allows  the  physician
o  intervene  before  the  patient  presents  a  serious  clinical
omplication.  This  routine  analysis  of  transplanted  patients
llows  for  a  higher  survival  rate  of  the  patients  and  the
rafts.thical disclosure
rotection  of  human  and  animal  subjects.  The  authors
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